INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.35
+1.27 (+5.75%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close22.08
Open22.34
Bid17.39 x 900
Ask0.00 x 3100
Day's Range22.20 - 23.49
52 Week Range11.31 - 31.58
Volume1,806,534
Avg. Volume991,973
Market Cap1.8B
Beta (3Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)-3.88
Earnings DateFeb 21, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.90
Trade prices are not sourced from all markets
  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool4 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?

  • The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
    Motley Fool5 days ago

    The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference

    These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    # Insmed Inc ### NASDAQ/NGS:INSM View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Negative Short interest is moderately high for INSM with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding INSM is favorable, with net inflows of $5.77 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here's Why Insmed Rocketed 43% Higher on Monday
    Motley Fool8 days ago

    Here's Why Insmed Rocketed 43% Higher on Monday

    Investors are impressed with early sales numbers for the biotech's Arikayce antibiotic.

  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire9 days ago

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Jan. 7, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to three new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on January 2, 2019 to purchase an aggregate 5,500 shares of Insmed common stock at an exercise price of $13.97 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • ETF Trends9 days ago

    Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology

    Biotechnology stocks and sector-related ETFs were among the best performers Monday after Eli Lilly (NYSE: LLY) said it will acquire Loxo Oncology Inc. (NasdaqGS: LOXO) for $8 billion. Among the best performers ...

  • MarketWatch12 days ago

    Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter

    Shares of Insmed Incorporated shot up 18% in after-hours trading Friday after the company announced it expected sales of its antibacterial Arikayce to be $9.8 million for the fourth quarter, with $9.2 million in U.S. sales and $600,000 in sales outside the U.S. The drug is used to treat patients with a lung disease caused by a group of bacteria called Mycobacterium avium complex (MAC) and who do not respond to traditional treatment. Arikayce was granted accelerated approval by the FDA in September. Insmed said more than 500 U.S. patients had started treatment with the drug and approximately 600 physicians had written at least one prescription for the therapy as of Dec. 31. Shares of Insmed have fallen 51% in the past 12 months, while the iShares NASDAQ Biotech ETF has fallen 6.75%. The S&P 500 has fallen 7%.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019
    PR Newswire12 days ago

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019

    BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary unaudited net product sales for the fourth quarter of 2018, and shared the Company's strategic priorities for 2019. ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.

  • See what the IHS Markit Score report has to say about Insmed Inc.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Insmed Incorporated (INSM) A Good Stock To Buy?
    Insider Monkey28 days ago

    Is Insmed Incorporated (INSM) A Good Stock To Buy?

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • GlobeNewswirelast month

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on December 3, 2018 to purchase an aggregate 58,990 shares of Insmed common stock at an exercise price of $18.70 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • See what the IHS Markit Score report has to say about Insmed Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Insmed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Insmed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • ACCESSWIRE2 months ago

    Healthcare Stocks with Turnaround Potential

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for Insmed, Service Corporation International, EPR Properties, Nielsen Holdings Plc, NiSource, and Criteo S.A — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Insmed Announces Changes to its Board of Directors

    Elizabeth McKee Anderson has been appointed to Insmed’s board of directors, succeeding Myrtle Potter, who has retired as a member of the board following four years of service to Insmed due to the demands of her current role as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences. “I am excited to join Insmed’s board and bring my extensive strategic marketing and market access experience to the Company as it executes the launch of ARIKAYCE® (amikacin liposome inhalation suspension) and pursues potential regulatory submissions in Europe and Japan,” said Anderson. Donald Hayden, Jr. has stepped down as chairman of the board after 13 years of distinguished service and will continue to serve as a director.

  • GlobeNewswire2 months ago

    Insmed to Present at Three November Conferences

    BRIDGEWATER, N.J., Nov. 06, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of INSM earnings conference call or presentation 30-Oct-18 12:30pm GMT

    Q3 2018 Insmed Inc Earnings Call

  • GuruFocus.com2 months ago

    Insmed Inc (INSM) President & CEO William Lewis Bought $249,630 of Shares

    President & CEO of Insmed Inc (NASDAQ:INSM) William Lewis bought 15,700 shares of INSM on 11/01/2018 at an average price of $15.9 a share.

  • Associated Press3 months ago

    Insmed: 3Q Earnings Snapshot

    On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of $1.14. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire3 months ago

    Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update

    —Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch— BRIDGEWATER, N.J., Oct. 30, 2018 -- Insmed.

  • See what the IHS Markit Score report has to say about Insmed Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    Insmed Inc NASDAQ/NGS:INSM

  • GlobeNewswire3 months ago

    Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018

    Insmed Incorporated (INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its third quarter 2018 financial results on Tuesday, October 30, 2018. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, October 30, 2018 to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 2556408.